These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22160043)

  • 1. Eosinophilic myeloproliferative disorders.
    Klion AD
    Hematology Am Soc Hematol Educ Program; 2011; 2011():257-63. PubMed ID: 22160043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
    Gotlib J
    Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary eosinophilic disorders: a concise review.
    Pardanani A; Tefferi A
    Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
    Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
    J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modern diagnosis and treatment of primary eosinophilia.
    Tefferi A
    Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations and Flame Figures: A Spectrum of Eosinophilic Dermatoses Whose Features Overlap With Wells' Syndrome.
    Smith SM; Kiracofe EA; Clark LN; Gru AA
    Am J Dermatopathol; 2015 Dec; 37(12):910-4. PubMed ID: 25839890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
    Yamada Y; Cancelas JA
    Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
    Miyazawa K; Kakazu N; Ohyashiki K
    Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic hypereosinophilic syndrome and "eosinophilic leukemia".
    Cassi E; De Paoli A; Fava S; Luoni M; Tosi A; Turri C; Grimi E
    Haematologica; 1992; 77(5):430-2. PubMed ID: 1483595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
    von Bubnoff N; Sandherr M; Schlimok G; Andreesen R; Peschel C; Duyster J
    Leukemia; 2005 Feb; 19(2):286-7. PubMed ID: 15618966
    [No Abstract]   [Full Text] [Related]  

  • 14. Murine models of eosinophilic leukemia: a model of FIP1L1-PDGFRα initiated chronic eosinophilic leukemia/systemic mastocytosis.
    Yamada Y; Cancelas JA; Rothenberg ME
    Methods Mol Biol; 2014; 1178():309-20. PubMed ID: 24986627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
    Klion AD; Noel P; Akin C; Law MA; Gilliland DG; Cools J; Metcalfe DD; Nutman TB
    Blood; 2003 Jun; 101(12):4660-6. PubMed ID: 12676775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypereosinophilic syndrome or chronic eosinophilic leukemia: report of a case with a lytic bone lesion.
    Juneja S; Stewart J; McKenzie A; Venter D; Januszewicz H
    Leukemia; 1997 May; 11(5):765-6. PubMed ID: 9180305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in diagnosis and treatment of eosinophilia.
    Sheikh J; Weller PF
    Curr Opin Hematol; 2009 Jan; 16(1):3-8. PubMed ID: 19057198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders.
    Reiter A; Grimwade D; Cross NC
    Haematologica; 2007 Sep; 92(9):1153-8. PubMed ID: 17768117
    [No Abstract]   [Full Text] [Related]  

  • 20. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.